Angiotensin-(1-7): The Counter-Regulatory RAS Peptide — Cardiovascular, Metabolic, and Neuroprotection Research

# Angiotensin-(1-7): The Counter-Regulatory RAS Peptide — Cardiovascular, Metabolic, and Neuroprotection Research

The renin-angiotensin system (RAS) is one of the most studied hormonal cascades in biomedical research, historically understood as a vasoconstrictor pathway culminating in Angiotensin II (Ang II) activity at the AT1 receptor. For decades, this classical arm dominated RAS pharmacology — yet a counter-regulatory axis operating in parallel received comparatively little attention until the early 2000s.

Angiotensin-(1-7) [Ang-(1-7)], a bioactive heptapeptide with the amino acid sequence Asp-Arg-Val-Tyr-Ile-His-Pro, has emerged as the central effector of this counter-regulatory arm. Where Ang II promotes vasoconstriction, inflammation, fibrosis, and oxidative stress, Ang-(1-7) generally counteracts these effects through its primary receptor: the Mas receptor, a G protein-coupled receptor (GPCR) encoded by the Mas proto-oncogene.

The discovery that Ang-(1-7) is an endogenous ligand for the Mas receptor — a landmark finding published in 2003 by Santos et al. in PNAS (PMID: 12829792) — fundamentally reframed how researchers conceptualize RAS biology. The subsequent identification of angiotensin-converting enzyme 2 (ACE2) as the primary enzyme generating Ang-(1-7) from Ang II further elevated the physiological relevance of this axis.

Today, the ACE2/Ang-(1-7)/Mas axis is a focus of intense research across cardiovascular biology, metabolic disease, neurodegeneration, renal function, and post-COVID-19 pathophysiology. This article provides a research-oriented overview of Ang-(1-7)'s biochemistry, receptor pharmacology, and the current state of preclinical and translational investigation.

> Research Use Only (RUO) Notice: Angiotensin-(1-7) is a research chemical for laboratory investigation only. All information presented here is for scientific and educational purposes. This content does not constitute medical advice, and Ang-(1-7) is not approved for human therapeutic use outside of controlled clinical trial settings.

---

Biochemistry: Structure and Biosynthesis

Ang-(1-7) is a heptapeptide cleaved from larger angiotensin precursors by multiple enzymatic routes:

• •ACE2 → Ang-(1-7) from Ang II: The most studied pathway. ACE2 cleaves the C-terminal phenylalanine from Angiotensin II (octapeptide) to yield Ang-(1-7). ACE2 has far higher catalytic efficiency for this reaction than for generating Ang-(1-7) from Ang I.
• •ACE2 + neprilysin → Ang-(1-7) from Ang I: Ang I can be first converted to Ang-(1-9) by ACE2, then to Ang-(1-7) by angiotensin-converting enzyme (ACE) or neutral endopeptidase.
• •Neprilysin and prolyl endopeptidase: These enzymes can also generate Ang-(1-7) from various angiotensin precursors, providing ACE2-independent biosynthetic routes.

The peptide's primary metabolic fate is hydrolysis by ACE into the inactive fragment Ang-(1-5), which limits its circulating half-life to approximately 30–60 seconds in plasma in preclinical models. This short half-life has been a central challenge for researchers studying its systemic effects and has driven development of cyclic and modified analogs with improved stability.

Molecular Profile

---

The ACE2/Ang-(1-7)/Mas Axis: A Counter-Regulatory System

The modern understanding of RAS is dual: a classical "pressor" arm (renin → Ang I → ACE → Ang II → AT1R) opposed by a "depressor" arm (ACE2 → Ang-(1-7) → Mas receptor). This conceptual framework was comprehensively reviewed in the landmark 2018 Physiological Reviews paper by Santos et al. (PMID: 29351514), which remains the definitive reference on this axis.

Mas Receptor Signaling

The Mas receptor is a GPCR that, upon Ang-(1-7) binding, activates multiple intracellular signaling cascades, including:

• •PI3K/Akt pathway: Mediates cardioprotective, anti-apoptotic, and insulin-sensitizing effects
• •eNOS activation: Increases endothelial nitric oxide (NO) production, contributing to vasodilation
• •MAPK modulation: Generally suppresses pro-inflammatory ERK1/2 signaling activated by Ang II/AT1R
• •PKA/cAMP: Implicated in renal and neurological effects
• •β-arrestin recruitment: Ang-(1-7) can also act as a biased agonist at AT1R via β-arrestin, exerting cardioprotective effects distinct from the canonical Mas receptor pathway (Santos et al., Scientific Reports, 2017)

Critically, Ang-(1-7)/Mas signaling often directly antagonizes or counterbalances AT1R/Ang II-driven pathways, creating a functional opposition that has made this axis a compelling research target across organ systems.

Tissue Expression

The ACE2/Ang-(1-7)/Mas axis is expressed broadly, with particularly high relevance in:

• •Cardiovascular tissue: Heart, vasculature, endothelium
• •Kidney: Proximal tubule epithelium, glomeruli
• •Brain: Hippocampus, cortex, hypothalamus, brainstem
• •Lung: Alveolar epithelium, pulmonary vasculature
• •Liver and adipose tissue: Relevant to metabolic regulation

---

Cardiovascular Research

Vasodilation and Blood Pressure Regulation

Ang-(1-7) consistently produces vasodilation in preclinical models through NO-dependent and NO-independent mechanisms. It counteracts Ang II-mediated vasoconstriction at both vascular smooth muscle and endothelial levels. Early research demonstrating these vascular effects was reviewed by Ferrario and colleagues (PMID: 17293687), who proposed Ang-(1-7) as a vasodilatory counterbalance to Ang II in cardiovascular disease.

Preclinical data in hypertensive models consistently show:

• •Reductions in mean arterial pressure
• •Improved endothelial function and NO bioavailability
• •Decreased vascular oxidative stress markers
• •Attenuated vascular remodeling and smooth muscle hypertrophy

Cardiac Hypertrophy and Remodeling

One of the most replicated findings in preclinical Ang-(1-7) research is its ability to limit pathological cardiac hypertrophy. Adenoviral delivery studies demonstrated that increased cardiac Ang-(1-7) signaling inhibits cardiomyocyte hypertrophy through both Mas receptor and AT2R pathways (PMC3447802). Mechanistically, this involves suppression of Ang II/AT1R-driven MAPK signaling and activation of Akt-mediated cytoprotective pathways.

Ang-(1-7) has also been studied for anti-fibrotic properties in cardiac tissue, with preclinical data suggesting it reduces TGF-β–mediated fibrosis and collagen deposition — effects potentially relevant to heart failure with preserved ejection fraction (HFpEF) models.

Heart Failure and Cardiometabolic Research

A 2026 Current Hypertension Reports review on therapeutic opportunities targeting the ACE2/Ang-(1-7)/MasR pathway in cardiometabolic disease (Springer Nature Link) highlights that augmenting this axis in preclinical models:

• •Improves endothelial function
• •Limits cardiac remodeling
• •Enhances insulin sensitivity
• •Reduces renal injury
• •Mitigates hepatic steatosis in MASH/NAFLD models

Early-phase clinical trials of Ang-(1-7) analogs (including TXA127/talfirastide) have demonstrated favorable safety profiles and pharmacodynamic target engagement, though definitive clinical outcomes data remain under investigation.

Atrial Natriuretic Peptide (ANP) Interaction

Research has demonstrated that Ang-(1-7) stimulates atrial natriuretic peptide (ANP) secretion via a Mas/PI3-kinase/Akt pathway, providing an additional mechanism by which it may modulate cardiovascular homeostasis (PMID: 20190099). This interaction links the counter-regulatory RAS to natriuretic peptide signaling — two complementary cardioprotective systems increasingly studied together.

---

Metabolic and Endocrine Research

Insulin Sensitization and Glucose Homeostasis

Ang-(1-7) has attracted substantial interest in metabolic research. Activation of the ACE2/Ang-(1-7)/Mas axis has been shown in preclinical models to:

• •Increase glucose utilization
• •Reduce insulin resistance at the peripheral level
• •Improve lipid profiles
• •Modulate adipocyte metabolism through PPAR-γ-related pathways (PMID: 22119778)

The mechanism appears to involve opposing the insulin-desensitizing effects of Ang II, which impairs insulin signaling via AT1R-mediated serine phosphorylation of IRS-1. This mechanistic insight has positioned Ang-(1-7) as a candidate for metabolic syndrome and type 2 diabetes research.

Central Cardiometabolic Control

Research published in 2024 (PMC11677932) on "Angiotensin-(1-7) and Central Control of Cardiometabolic Outcomes" highlights that centrally acting Ang-(1-7) modulates:

• •Sympathetic nervous system tone
• •Appetite and energy balance regulation
• •Energy expenditure
• •Adipogenesis and lipid storage

These central effects position Ang-(1-7) not only as a peripheral metabolic modulator but also as a brain-active peptide with relevance to obesity and metabolic syndrome research beyond peripheral tissue targets.

Obesity and MASH/NAFLD Models

Preclinical data consistently demonstrate that RAS imbalance — elevated Ang II with reduced Ang-(1-7) — correlates with metabolic dysfunction in obese animal models. Conversely, augmenting Ang-(1-7) or ACE2 activity tends to reverse features of metabolic syndrome, including hepatic steatosis, adipose tissue inflammation, and dysglycemia. These findings have generated substantial interest in Ang-(1-7) as a research tool for studying MASH/NAFLD and obesity-related cardiometabolic pathology.

---

Neuroprotection Research

Central Nervous System Expression of the ACE2/Mas Axis

ACE2 and Mas receptor are expressed throughout the brain, including the hippocampus, cortex, hypothalamus, and brainstem. This neurological expression pattern has generated significant research interest in Ang-(1-7) as a neuropeptide relevant to neuroinflammation, oxidative stress, and cognitive function.

A comprehensive 2025 Frontiers in Physiology review (frontiersin.org, 2025) on "Angiotensin-(1-7) protective effects in neurocognitive disorders" synthesizes preclinical evidence showing that Ang-(1-7)/Mas receptor activation:

• •Attenuates neuroinflammation via suppression of NF-κB and microglial activation
• •Reduces neuronal oxidative stress
• •Modulates autophagy and apoptosis pathways in neural tissue
• •Demonstrates potential relevance in Alzheimer's disease and vascular cognitive impairment models

The role of brain RAS dysregulation in neurodegenerative disease has made Ang-(1-7) research increasingly relevant to the neuroscience community.

Diabetes-Associated Cognitive Impairment

A 2024 study (PMC12035909) specifically examined central Ang-(1-7)/Mas receptor signaling in diabetes-associated cognitive impairment, finding that:

• •MasR activation alleviates synaptic damage in diabetic animal models
• •The AKT/FOXO1/PACAP axis mediates neuroprotective effects
• •Central Ang-(1-7) improved memory performance and synaptic marker expression

This work directly connects Ang-(1-7)'s metabolic and neuroprotective dimensions, suggesting the peptide is mechanistically relevant to the cognitive comorbidities of type 2 diabetes.

Stroke Research

Ang-(1-7) research in ischemic stroke models has shown promising reductions in infarct volume, oxidative damage, and post-ischemic neuroinflammation. The ongoing TXA127 clinical program includes a stroke indication, providing translational validation of these preclinical findings. The ACE2/Ang-(1-7) axis is further implicated in cerebroprotection via improving cerebrovascular endothelial function and reducing blood-brain barrier permeability in injury models.

---

Renal and Anti-Inflammatory Research

Renal Protection

ACE2 is highly expressed in the kidney, particularly in proximal tubule cells, where the Ang-(1-7)/Mas axis exerts protective effects against:

• •Diabetic nephropathy
• •Hypertensive renal damage
• •Tubular and glomerular fibrosis (via TGF-β inhibition)
• •Tubular oxidative stress and inflammation

The Ang-(1-7)/Mas axis appears to oppose Ang II-driven renal vasoconstriction, mesangial cell proliferation, and podocyte injury, making it a research target in chronic kidney disease models.

Broad Anti-Inflammatory and Anti-Fibrotic Mechanisms

The 2013 review on "ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis" (PMID: 23488800) documents Ang-(1-7)/Mas signaling in:

• •Suppressing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)
• •Inhibiting NF-κB transcriptional activity
• •Reducing macrophage and neutrophil inflammatory activation
• •Limiting fibrogenic TGF-β signaling in lung, heart, kidney, and liver tissue

These broad anti-inflammatory effects have also generated interest in pulmonary fibrosis research and skeletal muscle atrophy studies (PMID: 26851244), further expanding the research utility of the Ang-(1-7) model.

---

ACE2, SARS-CoV-2, and the Disrupted Ang-(1-7) Axis

The COVID-19 pandemic substantially elevated research interest in ACE2 and Ang-(1-7). SARS-CoV-2 enters host cells via ACE2 as its primary receptor (PMID: 32125455), with several downstream consequences for RAS balance:

1. ACE2 downregulation: SARS-CoV-2 binding and cellular internalization reduce surface ACE2 expression

2. Ang II accumulation: With less ACE2 activity, Ang II is less efficiently converted to Ang-(1-7)

3. Ang-(1-7) deficiency: Reduced Ang-(1-7) availability diminishes counter-regulatory Mas receptor signaling

4. Pathological amplification: This imbalance may amplify vascular inflammation, cytokine release, and organ injury in severe COVID-19

Research groups investigated whether restoring the ACE2/Ang-(1-7)/Mas axis could mitigate COVID-19-related cardiovascular and pulmonary complications. While this has not yielded definitive clinical therapies, it dramatically expanded ACE2/Ang-(1-7) research beyond traditional cardiovascular fields and introduced the axis to immunologists, pulmonologists, and infectious disease researchers.

The JACC review of SARS-CoV-2/RAS interactions (doi:10.1016/j.jacc.2020.04.028) provides comprehensive clinical context for this intersection.

---

Stability, Half-Life, and Analog Development

The Half-Life Challenge

The primary limitation of Ang-(1-7) as a laboratory tool is its extremely short plasma half-life, driven by rapid ACE-mediated cleavage to inactive Ang-(1-5). This degradation limits systemic study design and has driven considerable effort toward stable analogs and alternative delivery strategies.

Pharmacological Tools: AVE 0991 and CGEN-856S

AVE 0991 is a non-peptide Mas receptor agonist developed as a pharmacological tool that produces Ang-(1-7)-like effects without peptide stability limitations. It has been extensively used to characterize Mas receptor biology in preclinical research.

CGEN-856S is a cyclic peptide analog designed to mimic Ang-(1-7) activity with enhanced metabolic stability, developed primarily for preclinical mechanistic studies.

TXA127 (Talfirastide)

TXA127 (generic name: talfirastide), developed by Constant Therapeutics, is a pharmaceutical-grade Ang-(1-7) formulation in clinical development for:

• •Duchenne muscular dystrophy (DMD): Leveraging anti-fibrotic and muscle-protective preclinical data
• •Stroke: Based on neuroprotective preclinical findings
• •Pulmonary fibrosis: Exploring anti-fibrotic mechanisms in the lung

TXA127 early-phase trials have demonstrated favorable safety profiles and pharmacodynamic target engagement. Ongoing trials (as of 2026) are expected to yield important translational data.

Delivery Strategies for Research Use

For laboratory applications, Ang-(1-7) is typically administered via:

• •Acute intravenous or intra-arterial injection: For short-duration pharmacological studies
• •Subcutaneous osmotic pump infusion: For chronic delivery in rodent models
• •Cyclodextrin inclusion complexes: Developed to extend stability for oral administration research
• •Intracerebroventricular (ICV) infusion: For centrally-targeted neurological studies

---

Research Applications Summary

Cardiovascular Models

• •Hypertension models (spontaneously hypertensive rat, Ang II-infusion)
• •Cardiac hypertrophy and heart failure models
• •Atherosclerosis studies
• •Ischemia-reperfusion injury

Metabolic Research

• •STZ-induced and genetic diabetic models
• •High-fat diet obesity models
• •Insulin resistance assays
• •MASH/NAFLD hepatic models

Neurological Research

• •Alzheimer's disease and cognitive impairment models
• •Ischemic stroke models
• •Neuroinflammation assays
• •Diabetes-associated cognitive decline

In Vitro Applications

• •Endothelial cells: eNOS activation, inflammation markers, NO production
• •Cardiomyocytes: hypertrophy, apoptosis, oxidative stress
• •Hepatocytes: steatosis, insulin signaling
• •Neurons: neuroprotection, apoptosis, synaptic function
• •Adipocytes: PPAR-γ, lipogenesis, inflammatory cytokines

---

Related Peptides in This Research Domain

Angiotensin-(1-7) research frequently intersects with other peptides studied in overlapping disease models:

• •Natriuretic Peptides (ANP/BNP/CNP): Both systems modulate cardiac remodeling and cardiovascular homeostasis; Ang-(1-7) may stimulate ANP secretion.
• •GLP-1 Receptor Agonists: Shared metabolic research territory; both axes influence insulin sensitivity and cardiovascular protection with overlapping model systems.
• •Humanin: Another endogenous cytoprotective peptide with cardiovascular and neuroprotective properties studied in overlapping preclinical disease models.
• •Vasoactive Intestinal Peptide (VIP): Another vasodilatory neuropeptide; comparison studies exploring complementary protective mechanisms represent an active research area.

---

Conclusion: The Scientific Significance of Angiotensin-(1-7)

Angiotensin-(1-7) represents one of the most mechanistically compelling research peptides in modern biomedical science. As the principal effector of the counter-regulatory RAS arm, it provides a natural functional counterbalance to the pressor and pro-fibrotic effects of Ang II — operating across cardiovascular, metabolic, renal, and neurological tissues through a coherent molecular framework anchored to the Mas receptor.

Its discovery as an endogenous Mas ligand, the identification of ACE2 as its primary biosynthetic enzyme, and the COVID-19 spotlight on ACE2 biology have collectively elevated the ACE2/Ang-(1-7)/Mas axis to one of the most studied systems in translational medicine. The growing clinical pipeline — particularly the TXA127 program — signals that preclinical promise is beginning to be tested rigorously in human disease contexts.

For research laboratories investigating cardiovascular pharmacology, metabolic disease, renal pathology, or neurodegeneration, Ang-(1-7) offers a mechanistically distinct, translationally relevant, and experimentally tractable research target with a rich and growing evidence base spanning decades of high-quality investigation.

---

All research chemicals and peptides discussed in this article are for Research Use Only (RUO) — intended exclusively for laboratory investigation by qualified researchers. They are not intended for human or animal therapeutic use.